PHASE 2 STUDY OF NIVOLUMAB (ANTI-PROGRAMMED DEATH-1 [PD-1]) IN PATIENTS (PTS) WITH ADVANCED, REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC)

被引：1
|
作者：
Zalcman, G. [1 ]
Rizvi, N. A. [2 ]
Lena, H. [3 ]
Wolf, J. [4 ]
Mazieres, J. [5 ]
Antonia, S. J. [6 ]
Minenza, E. [7 ]
Planchard, D. [8 ]
Lestini, B. J. [9 ]
Ramalingam, S. S. [10 ]
机构：
[1] CHU Caen, Pneumonol, F-14000 Caen, France
[2] Mem Sloan Kettering Canc Ctr, Thorac Oncol, New York, NY 10021 USA
[3] Ctr Hosp Univ Rennes, Oncol & Pulmonol, Rennes, France
[4] Univ Klin Koeln, Pulm Oncol, Cologne, Germany
[5] Ctr Hosp Univ Toulouse, Hop Larrey, Thorac Oncol, Toulouse, France
[6] Univ S Florida, H Lee Moffitt Canc Ctr, Thorac Oncol, Tampa, FL 33682 USA
[7] Osped S Maria, Oncol, Terni, Italy
[8] Gustave Roussy, Thorac Oncol, Villejuif, France
[9] Bristol Myers Squibb Co, Oncol Global Clin Res, Princeton, NJ USA
[10] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv050.8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
104PD
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection
    Lipson, Evan J.
    Naqvi, Fizza F.
    Loss, Manisha J.
    Schollenberger, Megan D.
    Pardoll, Drew M.
    Moore, Jack, Jr.
    Brennan, Daniel C.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 (08) : 2264 - 2268
  • [32] Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
    Ramalingam, S. S.
    Mazieres, J.
    Planchard, D.
    Stinchcombe, T. E.
    Dy, G. K.
    Antonia, S. J.
    Horn, L.
    Lena, H.
    Minenza, E.
    Mennecier, B.
    Otterson, G. A.
    Campos, L. T.
    Gandara, D. R.
    Levy, B. P.
    Nair, S. G.
    Zalcman, G.
    Wolf, J.
    Baudelet, C.
    Lestini, B. J.
    Rizvi, N. A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 (05): : 1266 - 1267
  • [33] Predictive Utility of c-reactive Protein (CRP) in Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1) Therapy
    Naqash, A. R.
    Stroud, C. R. G.
    Cherry, C.
    Muzaffar, M.
    Bowling, M.
    Walker, P. R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1559 - S1559
  • [34] Investigation of Programmed Cell Death-1 (PD-1) Gene Variations at Positions PD1.3 and PD1.5 in Iranian Patients with Non-small Cell Lung Cancer
    Pirdelkhosh, Zahra
    Kazemi, Tohid
    Haghshenas, Mohammad Reza
    Ghayumi, Mohammad Ali
    Erfani, Nasrollah
    [J]. MIDDLE EAST JOURNAL OF CANCER, 2018, 9 (01) : 13 - 17
  • [35] Autoimmune diabetes and anti-programmed cell death-1 (anti-PD-1) cancer immunotherapy
    Daltry, S.
    Bujanova, J.
    Cranston, I.
    [J]. DIABETIC MEDICINE, 2017, 34 : 102 - 102
  • [36] Thyroid autoantibodies at baseline predict longer survival in non-small cell lung cancer patients treated with anti-programmed cell death-1 blockade: a prospective study
    Okuji, Takayuki
    Iwama, Shintaro
    Kobayashi, Tomoko
    Yasuda, Yoshinori
    Ito, Masaaki
    Yamagami, Ayana
    Ando, Masahiko
    Hase, Tetsunari
    Shibata, Hirofumi
    Hatta, Takahiro
    Zhou, Xin
    Onoue, Takeshi
    Kawaguchi, Yohei
    Miyata, Takashi
    Sugiyama, Mariko
    Hagiwara, Daisuke
    Suga, Hidetaka
    Banno, Ryoichi
    Ando, Yuichi
    Hashimoto, Naozumi
    Arima, Hiroshi
    [J]. NAGOYA JOURNAL OF MEDICAL SCIENCE, 2024, 86 (03): : 452 - 463
  • [37] Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Chia, Puey Ling
    John, Thomas
    [J]. JOURNAL OF IMMUNOTHERAPY, 2016, 39 (05) : 202 - 204
  • [38] A phase I/II study of the anti-programmed cell death-1 (PD-1) antibody AK105 in patients with relapsed or refractory classic Hodgkin lymphoma (cHL).
    Song, Yuqin
    Zhu, Jun
    Lin, Ningjing
    Zhang, Chen
    Jin, Xiaoping
    Xu, Shuping
    Li, Baiyong
    Xia, Yu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] Integrated safety analysis of anti-programmed cell death-1 (PD-1) antibody penpulimab in advanced solid tumour or lymphoma
    Xu, N.
    Han, B.
    Jiao, S.
    Hu, C.
    Mislang, A.
    Coward, J.
    Cooper, A.
    Underhill, C.
    Xia, Y.
    Xia, D.
    Jin, X.
    Wang, Z. M.
    Li, B.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1428 - S1429
  • [40] Updated results of subcutaneous (SC) anti-programmed cell death 1 (PD-1) receptor antibody PF-06801591 for locally advanced or metastatic non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC)
    Cho, B. C. Chul
    Penkov, K. D.
    Bondarenko, I.
    Kurochkin, A.
    Pikiel, J.
    Ahn, H. K.
    Li, R.
    Jacobs, I. A.
    Bowers, M.
    Li, M.
    Johnson, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S721 - S721
12345